News for Castle Biosciences Inc Stock (CSTL)

Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett's Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024

Business Wire • 05/14/24

Castle Biosciences' IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”

Business Wire • 05/10/24

Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result

Business Wire • 05/08/24

Wall Street Analysts Predict a 36.09% Upside in Castle Biosciences (CSTL): Here's What You Should Know

Zacks Investment Research • 05/07/24

Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable

Zacks Investment Research • 05/06/24

Castle Biosciences, Inc. (CSTL) Q1 2024 Earnings Call Transcript

Seeking Alpha • 05/04/24

DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck

Business Wire • 05/03/24

Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research • 05/02/24

Castle Biosciences Reports First Quarter 2024 Results

Business Wire • 05/02/24

Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood's Designation as a Sun Safe Leadership Model City by IMPACT Melanoma

Business Wire • 04/30/24

Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024

Business Wire • 04/11/24

Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations

Business Wire • 04/10/24

Castle Biosciences' Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year

Business Wire • 04/10/24

Presentations at EADO Highlight Potential Impact of Castle Biosciences' DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer

Business Wire • 04/04/24

Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

Business Wire • 04/02/24

Castle Biosciences Announces Updates to its Board of Directors

Business Wire • 03/27/24

Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year

Business Wire • 03/25/24

Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB

Business Wire • 03/22/24

Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy

Business Wire • 03/19/24

New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences' IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older

Business Wire • 03/15/24

Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum

Business Wire • 03/12/24

Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Business Wire • 03/08/24

In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups

Business Wire • 03/07/24

Castle Biosciences, Inc. (CSTL) Q4 2023 Earnings Call Transcript

Seeking Alpha • 02/29/24

Castle Biosciences, Inc. (CSTL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research • 02/29/24